For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

The same cell product could potentially be used to treat multiple solid tumors like ovarian, pancreatic and lung cancers.

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its ...

SPRINGFIELD, Mo.--(BUSINESS WIRE)--QPS Holdings, LLC announced today that their Springfield campus, QPS Missouri, has launched a new Cell Therapy business unit. The unit’s first achievement is the ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

In recent years, Cell, Tissue and Gene Therapy (CTGT) treatments and products have experienced rapid growth both in China and around the globe. According to a report by China's Center for Drug ...

First data from phase 1b/2 EPCORE NHL-4: Epcoritamab (Epcor) in Chinese patients (Pts) with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). This is an ASCO Meeting Abstract from the ...

Publication demonstrates the cell therapy product for Parkinson’s Disease overcomes most complex challenges in bioproduction, while demonstrating full behavioral recovery in pre-clinical model ...

Automation will help the cell therapy sector reduce production costs, resulting in lower-priced products that increase patient accessibility.

The cell and gene therapy quality control market size is calculated at USD 2.87 billion in 2025 and is expected to reach ...